Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation method aims to shrink large tumors better

NCT ID NCT07594431

Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This phase 2 trial compares a new type of radiation called LATTICE radiotherapy with standard palliative radiation for people who have large metastatic tumors (over 2.5 cm). The LATTICE method delivers a very high dose to the center of the tumor while keeping lower doses to the surrounding area. The study will enroll 80 patients and measure how much the tumor shrinks 90 days after treatment. The goal is to see if this approach works better than the standard treatment for controlling tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LATTICE radiotherapy (a type of radiation that delivers a high dose to the center of the tumor while keeping lower doses to surrounding tissue)
What this could lead to
If it works, this could offer a more effective way to shrink large metastatic tumors, potentially improving symptom control and quality of life.
What could go wrong
This is a small, early-phase trial with only 80 participants, so results may not apply to everyone. The higher radiation dose could also increase side effects like pain or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

80 patients with confirmed metastatic tumor (\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included. Inclusion Criteria: * Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer * One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis * Age ≥12 * ECOG Performance Status 0-2 * For patients age 12-16, Lansky Play-Performance score 50-100 * Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential * All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent. Exclusion criteria: * Prior radiation therapy to the tumor to be treated * Active pregnancy * Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome * The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastases Metastatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.